Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Status:
Active, not recruiting
Trial end date:
2022-07-02
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear
translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR
positive, triple negative breast cancers (TNBC).
Secondary Objectives:
1. To examine the safety and tolerability of dasatinib in patients with operable TNBC
2. To explore potential intracellular mechanisms which impact dasatinib effect on cellular
localization of EGFR in operable TNBC.
3. To examine the pathologic complete response (pCR) rates to standard neoadjuvant
chemotherapy in nEGFR+ TNBC
4. To examine breast cancer recurrence rates and patterns of metastatic recurrent in nEGFR+
TNBC